Chen Jianjun, Zhou Yue, Zhang Li, Wang Yanjun, Pepper Amber N, Cho Seong H, Kong Weijia
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Division of Allergy, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Allergy Asthma Immunol Res. 2017 Sep;9(5):403-409. doi: 10.4168/aair.2017.9.5.403.
Nasal cytology is important in the diagnosis and treatment of nasal inflammatory diseases. Treatment of allergic rhinitis (AR) according to nasal cytology has not been fully studied. We plan to explore the individualized treatment of AR according to nasal cytology.
Nasal cytology from 468 AR patients was examined for inflammatory cell quantity (grade 0-5) and the percentage of neutrophils and eosinophils. Results were subdivided into the following categories: AR(Eos), eosinophil ≥50% of the whole inflammatory cells; AR(Neu), neutrophils ≥90%; AR(Eos/Neu), 10%≤ eosinophil <50%; AR(Low), grade 0/1 inflammatory cell quantity. Nasal cytology-guided treatment was implemented: all AR(Eos) patients (n=22) and half of the AR(Neu) patients (AR[Neu1], n=22) were treated with mometasone furoate spray and oral loratadine. Another half of the AR(Neu) patients (AR[Neu2], n=22) were treated with oral clarithromycin. Visual analog scale (VAS), symptom scores, and nasal cytology were evaluated 2 weeks before and after treatment.
There were 224/468 (47.86%) AR(Eos), 67/468 (14.32%) AR(Neu), 112/468 (23.93%) AR(Eos/Neu), and 65/468 (13.89%) AR(Low) of the AR patients studied. There were no significant differences in clinical characteristics among these subgroups, except that the nasal blockage score was higher in AR(Eos) patients than in AR(Neu) patients (1.99 vs 1.50, P=0.02). Comparing AR(Eos) patients with AR(Neu1) patients 2 weeks after treatment, nasal symptoms and VAS were significantly lower in AR(Eos) patients, except for nasal blockage symptoms (P<0.05 of nasal itching and sneezing; P<0.01 for nasal secretion, total scores, and VAS). Comparing AR(Neu1) with AR(Neu2) patients, nasal symptoms, and VAS were significantly lower in AR(Neu2), except for nasal blockage and nasal itching symptoms (P<0.05 for nasal secretions, sneezing, total score, and VAS).
Nasal cytology may have important value in subtyping AR and optimizing AR treatment. Treating neutrophils is very important in AR patients with locally predominant neutrophils.
鼻细胞学检查在鼻炎性疾病的诊断和治疗中具有重要意义。根据鼻细胞学检查结果对变应性鼻炎(AR)进行治疗的研究尚不充分。我们计划探索根据鼻细胞学检查结果对AR进行个体化治疗。
对468例AR患者的鼻细胞学检查结果进行分析,检测炎性细胞数量(0 - 5级)以及中性粒细胞和嗜酸性粒细胞的百分比。结果分为以下几类:AR(嗜酸性粒细胞型),嗜酸性粒细胞占全部炎性细胞的≥50%;AR(中性粒细胞型),中性粒细胞≥90%;AR(嗜酸性粒细胞/中性粒细胞混合型),嗜酸性粒细胞占10%≤且<50%;AR(低炎症细胞量型),炎性细胞数量为0/1级。实施鼻细胞学检查指导下的治疗:所有AR(嗜酸性粒细胞型)患者(n = 22)和一半的AR(中性粒细胞型)患者(AR[中性粒细胞型1],n = 22)接受糠酸莫米松喷雾剂和口服氯雷他定治疗。另一半AR(中性粒细胞型)患者(AR[中性粒细胞型2],n = 22)接受口服克拉霉素治疗。在治疗前后2周评估视觉模拟量表(VAS)、症状评分和鼻细胞学检查结果。
在所研究的AR患者中,有224/468(47.86%)为AR(嗜酸性粒细胞型),67/468(14.32%)为AR(中性粒细胞型),112/468(23.93%)为AR(嗜酸性粒细胞/中性粒细胞混合型),65/468(13.89%)为AR(低炎症细胞量型)。这些亚组之间的临床特征无显著差异,但AR(嗜酸性粒细胞型)患者的鼻塞评分高于AR(中性粒细胞型)患者(1.99对1.50,P = 0.02)。治疗2周后,比较AR(嗜酸性粒细胞型)患者与AR(中性粒细胞型1)患者,除鼻塞症状外,AR(嗜酸性粒细胞型)患者的鼻部症状和VAS显著更低(鼻痒和打喷嚏P<0.05;鼻分泌物、总分和VAS P<0.01)。比较AR(中性粒细胞型1)与AR(中性粒细胞型2)患者,除鼻塞和鼻痒症状外,AR(中性粒细胞型2)患者的鼻部症状和VAS显著更低(鼻分泌物、打喷嚏、总分和VAS P<0.05)。
鼻细胞学检查在AR的亚型分类和优化AR治疗方面可能具有重要价值。对于以局部中性粒细胞为主导的AR患者,治疗中性粒细胞非常重要。